Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.68−0.11 (-6.15%)
Close on Nov 13, 2026Market cap $2.74MP/E –Yield –
Earnings
Ernexa Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q4 FY2022
–
EPS, Q4 FY2022
-$1.24
-$0.16 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Ernexa Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2022ended Dec 31, 2022 | Mar 20, 2023after the close | – | – | -$1.24 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 15, 2022after the close | – | – | -$0.16 | Release |
| Q4 FY2021ended Dec 31, 2021 | Apr 15, 2022after the close | – | – | -$0.16 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 17, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 13, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 7, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 19, 2020after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 17, 2020after the close | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Oct 30, 2019after the close | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 9, 2019after the close | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 13, 2019after the close | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Mar 20, 2019after the close | – | – | – | Filing |
| Q3 FY2018ended Sep 30, 2018 | Nov 7, 2018after the close | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 2, 2018after the close | – | – | – | Filing |
| Q1 FY2018ended Mar 31, 2018 | May 9, 2018after the close | – | – | – | Filing |
| Q4 FY2017ended Dec 31, 2017 | Mar 6, 2018after the close | – | – | – | Filing |
| Q3 FY2017ended Sep 30, 2017 | Nov 7, 2017after the close | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Aug 2, 2017after the close | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | May 3, 2017after the close | – | – | – | Filing |
| Q4 FY2016ended Dec 31, 2016 | Mar 6, 2017after the close | – | – | – | Filing |
| Q3 FY2016ended Sep 30, 2016 | Nov 1, 2016before the open | – | – | – | Filing |
| Q2 FY2016ended Jun 30, 2016 | Aug 3, 2016after the close | – | – | – | Filing |
| Q1 FY2016ended Mar 31, 2016 | May 6, 2016before the open | – | – | – | Filing |
| Q4 FY2015ended Dec 31, 2015 | Mar 11, 2016before the open | – | – | – | Filing |
| Q3 FY2015ended Sep 30, 2015 | Nov 5, 2015after the close | – | – | – | Filing |
| Q2 FY2015ended Jun 30, 2015 | Aug 6, 2015after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Ernexa Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Ernexa Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Ernexa Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- News
- Update
- News
- Update
- Results
- Update
- Update
- Update
- Update
- Results
See a number that looks wrong?